ConvaTec Group PLC with ticker (LON:CTEC) now has a potential upside of 11.6% according to JP Morgan.
JP Morgan set a target price of 323 GBX for the company, which when compared to the ConvaTec Group PLC share price of 289 GBX at opening today (22/03/2024) indicates a potential upside of 11.6%. Trading has ranged between 195 (52 week low) and 291 (52 week high) with an average of 6,238,975 shares exchanging hands daily. The market capitalisation at the time of writing is £5,954,807,018.
Convatec Group Plc is a United Kingdom-based medical products and technologies company. The Company is engaged in the development, manufacture and sale of medical products, services, and technologies. It is focused on solutions for the management of chronic conditions. It markets and sells its solutions and services in four categories, such as Advanced Wound Care, Ostomy Care, Continence and Critical Care, and Infusion Care. Its Advanced Wound Care includes advanced solutions for the management of acute and chronic wounds resulting from ongoing conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. Ostomy Care includes devices, accessories and personalized services for individuals with a stoma. Its Continence and Critical Care includes products and services for people with urinary continence issues, and other devices for critical care. Its Infusion Care includes disposable infusion sets used in insulin pump therapy for people with diabetes.
ConvaTec Group PLC 11.6% potential upside indicated by JP Morgan
- Written by: Charlotte Edwards
Latest Company News
Convatec has appointed Dr Jens Viebke as a Non-Executive Director with immediate effect and added him to the Remuneration...
Convatec has outlined finance leadership changes, appointed Tobias Hestler as a Non-Executive Director and reaffirmed its 2026 expectations....
Convatec has introduced its new Accelerate strategy, outlining four strategic pillars and reaffirming medium-term guidance including 6–8% annual organic...
Convatec Group PLC reported FY2025 revenue of $2.44bn, up 6.5% on a reported basis, with adjusted operating profit rising...
Convatec has announced a non-discretionary share buyback of up to $300 million to return surplus capital to shareholders. The...
Convatec Group Plc celebrates the CMS's postponement of LCDs for diabetic foot ulcers, ensuring continued access to their trusted...










































